Insider transactions

EDGAR

MEDICUS PHARMA LTD.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–49 of 49

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-04 Filed 2026-09-08Bonner Carolyn F. Officer: President and CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares, no par value
Acquired (A)1,470,5880.1705
250,735.254

Derived: shares × price per share. Exact value 250735.2540.

1,489,493Direct (D) No— Open filing 0000950142-26-002519 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Bonner Carolyn F. Officer: President and CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (250,000) — exercise price 0.1705
Acquired (A)250,0000—250,000Direct (D) No
F1
  • F1 The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-002519 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Smith Andrew Alasdair Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares, no par value
Acquired (A)735,2940.1705
125,367.627

Derived: shares × price per share. Exact value 125367.6270.

735,458Direct (D) No— Open filing 0000950142-26-002522 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Smith Andrew Alasdair Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (125,000) — exercise price 0.1705
Acquired (A)125,0000—125,000Direct (D) No
F1
  • F1 The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-002522 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Brennan Edward J. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares, no par value
Acquired (A)588,2350.1705
100,294.0675

Derived: shares × price per share. Exact value 100294.0675.

674,735Direct (D) No— Open filing 0000950142-26-002520 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Brennan Edward J. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (100,000) — exercise price 0.1705
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-002520 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Bokhari Raza Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares, no par value
Acquired (A)2,941,1760.1705
501,470.508

Derived: shares × price per share. Exact value 501470.5080.

2,941,176Direct (D) No— Open filing 0000950142-26-002518 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Bokhari Raza Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (500,000) — exercise price 0.1705
Acquired (A)500,0000—500,000Direct (D) No
F1
  • F1 The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-002518 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Mehmud Faisal Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Shares, no par value
Acquired (A)1,470,5880.1705
250,735.254

Derived: shares × price per share. Exact value 250735.2540.

1,470,588Direct (D) No— Open filing 0000950142-26-002521 Read from the filing’s XML Dispute this row
2026-09-04 Filed 2026-09-08Mehmud Faisal Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (250,000) — exercise price 0.1705
Acquired (A)250,0000—250,000Direct (D) No
F1
  • F1 The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-002521 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Rodgers Cathy McMorris Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001642 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04FISHMAN BARRY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001636 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04MAHAFFY PATRICK J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001638 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Brennan Edward J. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.36
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001634 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Ciaruffoli Robert J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001635 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Bokhari Raza Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (500,000) — exercise price 0.36
Acquired (A)500,0000—500,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001632 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Bonner Carolyn F. Officer: President and CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (250,000) — exercise price 0.36
Acquired (A)250,0000—250,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001633 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04May Sara R. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001639 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Raju Ajay Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001641 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Smith Andrew Alasdair Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (200,000) — exercise price 0.36
Acquired (A)200,0000—200,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001643 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Ashton William Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001631 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Kaiser Larry Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.36
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001637 Read from the filing’s XML Dispute this row
2026-06-03 Filed 2026-06-04Mehmud Faisal Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (250,000) — exercise price 0.36
Acquired (A)250,0000—250,000Direct (D) No
F1
  • F1 The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-26-001640 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Rodgers Cathy McMorris Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001032 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01May Sara R. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001029 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Raju Ajay Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001031 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Bokhari Raza Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (325,000) — exercise price 0.50
Acquired (A)325,0000—325,000Direct (D) No— Open filing 0000950142-26-001022 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Kaiser Larry Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001027 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Mehmud Faisal Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (125,000) — exercise price 0.50
Acquired (A)125,0000—125,000Direct (D) No— Open filing 0000950142-26-001030 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Brennan Edward J. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001024 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Ciaruffoli Robert J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001025 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Ashton William Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001021 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01MAHAFFY PATRICK J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001028 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Bonner Carolyn F. Officer: President and CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (100,000) — exercise price 0.50
Acquired (A)100,0000—100,000Direct (D) No— Open filing 0000950142-26-001023 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01FISHMAN BARRY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 0.50
Acquired (A)25,0000—25,000Direct (D) No— Open filing 0000950142-26-001026 Read from the filing’s XML Dispute this row
2026-03-30 Filed 2026-04-01Smith Andrew Alasdair Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 0.50
Acquired (A)50,0000—50,000Direct (D) No— Open filing 0000950142-26-001033 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Smith Andrew Alasdair Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 1.80
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003241 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Mehmud Faisal Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (75,000) — exercise price 1.80
Acquired (A)75,0000—75,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003238 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18May Sara R. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003237 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Rodgers Cathy McMorris Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003240 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Kaiser Larry Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003235 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18MAHAFFY PATRICK J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003236 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Brennan Edward J. Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (50,000) — exercise price 1.80
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003232 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Bokhari Raza Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (125,000) — exercise price 1.80
Acquired (A)125,0000—125,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003230 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Ashton William Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003229 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Bonner Carolyn F. Officer: President and CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (75,000) — exercise price 1.80
Acquired (A)75,0000—75,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003231 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Raju Ajay Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003239 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18Ciaruffoli Robert J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003233 Read from the filing’s XML Dispute this row
2025-12-16 Filed 2025-12-18FISHMAN BARRY Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Shares (25,000) — exercise price 1.80
Acquired (A)25,0000—25,000Direct (D) No
F1
  • F1 The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.
Open filing 0000950142-25-003234 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-16. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–24 of 24

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Interchange Capital Partners, LLC 2,124,910 SH342,879 dollarsHigher by 538,039 Prior quarter: 1,586,871Open filing 0001845998-26-000006 Filed 2026-10-28 Dispute this row
Private Advisor Group, LLC 273,555 SH50,089 dollarsNot in the prior quarter’s filings read Open filing 0001567755-26-000005 Filed 2026-11-10 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager181,613 SH29,239 dollarsLower by 152,060 Prior quarter: 333,673Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Sterling Investment Advisors, Ltd. 100,000 SH16,100 dollarsUnchanged Prior quarter: 100,000Open filing 0001701132-26-000005 Filed 2026-10-27 Dispute this row
UBS Group AG Partly reported under another manager83,489 SH13,689 dollarsHigher by 81,286 Prior quarter: 2,203Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
COMMONWEALTH EQUITY SERVICES, LLC Partly reported under another manager73,863 SH11,890 dollarsHigher by 21,220 Prior quarter: 52,643Open filing 0000312272-26-000024 Filed 2026-11-02 Dispute this row
May Hill Capital, LLC 50,622 SH8,150 dollarsUnchanged Prior quarter: 50,622Open filing 0001754960-26-000973 Filed 2026-11-03 Dispute this row
Anson Funds Management LP 42,400 SH12,720 dollarsUnchanged Prior quarter: 42,400Open filing 0001193125-26-460605 Filed 2026-11-13 Dispute this row
STIFEL FINANCIAL CORP Partly reported under another manager30,000 SH4,830 dollarsUnchanged Prior quarter: 30,000Open filing 0000720672-26-000017 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager25,658 SH4,018 dollarsHigher by 36 Prior quarter: 25,622Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Wilmington Savings Fund Society, FSB Partly reported under another manager25,622 SH4,125 dollarsUnchanged Prior quarter: 25,622Open filing 0000900974-26-000008 Filed 2026-10-23 Dispute this row
Smithfield Trust Co 24,614 SH4 dollarsUnchanged Prior quarter: 24,614Open filing 0001019754-26-000005 Filed 2026-11-09 Dispute this row
Sound View Wealth Advisors Group, LLC 17,000 SH2,737 dollarsNot in the prior quarter’s filings read Open filing 0001784777-26-000003 Filed 2026-11-10 Dispute this row
Summit Global Investments 15,000 SH2 dollarsNot in the prior quarter’s filings read Open filing 0001697953-26-000007 Filed 2026-10-28 Dispute this row
LPL Financial LLC 11,012 SH1,773 dollarsLower by 6,500 Prior quarter: 17,512Open filing 0001403438-26-000005 Filed 2026-11-06 Dispute this row
Foundations Investment Advisors, LLC 11,000 SH1,771 dollarsUnchanged Prior quarter: 11,000Open filing 0001743404-26-000009 Filed 2026-11-12 Dispute this row
StoneX Group Inc. Partly reported under another manager10,965 SH1,765 dollarsLower by 6,101 Prior quarter: 17,066Open filing 0000913760-26-000042 Filed 2026-11-03 Dispute this row
STALEY CAPITAL ADVISERS INC 10,000 SH1,610 dollarsNot in the prior quarter’s filings read Open filing 0001106565-26-000010 Filed 2026-11-06 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager7,500 SH1,200 dollarsUnchanged Prior quarter: 7,500Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
Global Retirement Partners, LLC 1,000 SH161 dollarsNot in the prior quarter’s filings read Open filing 0001580642-26-007620 Filed 2026-11-10 Dispute this row
MORGAN STANLEY Partly reported under another manager1,000 SH161 dollarsLower by 22 Prior quarter: 1,022Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
HAZLETT, BURT WATSON, INC. 425 SH0 dollarsUnchanged Prior quarter: 425Open filing 0000046392-26-000006 Filed 2026-11-04 Dispute this row
BOLTON SECURITIES CORPORATION 100 SH16 dollarsUnchanged Prior quarter: 100Open filing 0001457457-26-000016 Filed 2026-11-12 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager0 SH0 dollarsLower by 400 Prior quarter: 400Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • XTX Topco Ltd 243,362 SH
  • ARMISTICE CAPITAL, LLC 60,600 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 31,462 SH
  • CITADEL ADVISORS LLC 25,102 SH
  • Stratos Wealth Partners, LTD. 20,950 SH
  • MARATHON CAPITAL MANAGEMENT 15,500 SH
  • Connective Capital Management, LLC 6,000 SH
  • ROYAL BANK OF CANADA 1,055 SH
  • MERCER GLOBAL ADVISORS INC /ADV 500 SH
  • WELLS FARGO COMPANY/MN 200 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Melani Kenneth R. Common Shares, no par value3.63,248,741.0009/30/2026 Filed 2026-10-16SCHEDULE 13G/AAmendment 2Open filing 0000950142-26-002781 Dispute this row
VELOCITY FUND PARTNERS, LP Common Shares, no par value3.22,839,330.0009/30/2026 Filed 2026-10-16SCHEDULE 13G/AAmendment 2Open filing 0000950142-26-002781 Dispute this row
BOKHARI, RAZA Common shares, no par value5.34,859,349.0009/04/2026 Filed 2026-09-14SCHEDULE 13DOpen filing 0000950142-26-002546 Dispute this row
RBx Capital, LP Common shares, no par value0.9793,173.0009/04/2026 Filed 2026-09-14SCHEDULE 13DOpen filing 0000950142-26-002546 Dispute this row
Raju Ajay Common Shares, no par value per share3.72,031,250.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 1Open filing 0000950142-26-001279 Dispute this row
215 Capital Togo PHL Fund I, LP Common Shares, no par value per share3.62,000,000.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 1Open filing 0000950142-26-001279 Dispute this row
Togo PHL Management LLC Common Shares, no par value per share3.62,000,000.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 1Open filing 0000950142-26-001279 Dispute this row
Bokhari Raza Common shares, no par value4.81,218,173.0012/31/2025 Filed 2026-01-05SCHEDULE 13G/AAmendment 1Open filing 0000950142-26-000046 Dispute this row
RBx Capital, LP Common shares, no par value3.2793,173.0012/31/2025 Filed 2026-01-05SCHEDULE 13G/AAmendment 1Open filing 0000950142-26-000046 Dispute this row
Armistice Capital, LLC Common shares, no par value4.99935,724.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-25-003590 Dispute this row
Steven Boyd Common shares, no par value4.99935,724.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-25-003590 Dispute this row
Melani Kenneth R. Common Shares, no par value18.23,248,741.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 1Open filing 0000950142-25-002133 Dispute this row
VELOCITY FUND PARTNERS, LP Common Shares, no par value15.92,839,330.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 1Open filing 0000950142-25-002133 Dispute this row
John Hathaway Common shares, no par value4.5800,952.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 1Open filing 0000950142-25-002132 Dispute this row
SkinJect Partners LLC Common shares, no par value4.5800,952.0006/30/2025 Filed 2025-08-12SCHEDULE 13G/AAmendment 1Open filing 0000950142-25-002132 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,139,981 filings read, dated 2004-06-14 to 2026-11-16: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202263,366
2023199,811
2024209,823
2025235,520
2026254,873

Filings made before the SEC required XML are listed, not extracted.

Back to MEDICUS PHARMA LTD.